FDA Intensifies Drive to Reduce REMS Burdens: The Key Objective Is to Ease Workflow Obstacles for Pharmacists.

摘要

The FDA is working to solve problems with the often-confusing risk evaluation and mitigation strategy program, which covers 74 pharmaceuticals and four drug classes. Issues include patient access to drugs and the dominant role of specialty pharmacies.